ATC Φάρμακα Δραστικές ICPC2 ICD10 Ιατρική στην Πράξη Νοσήματα Λοιμώξεις Εμβόλια Πρωτόκολλα
  • Omeprazole
  • indication:For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
  • pharmacologypharmacology:
  • mechanism: Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.
  • toxicity: Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.
  • absorprion: Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg.
  • halflife: 0.5-1 hour
  • roouteelimination: Urinary excretion is a primary route of excretion of omeprazole metabolites.
  • volumedistribution:
  • clearance: * total body cl=500-600 mL/min [healthy] * 250 mL/min [Geriatric] * 70 mL/min [Hepatic Impairment] * 10 - 62 mL/min/1.73 m2 [Renal Impairment]